It would be highly unlikely the company would use the current...

It would be highly unlikely the company would use the current vape in the trials.

There's no sensible business reason to do so.

Sure, it's a practical, safe (tamper proof pods) & reliable vape, so it's a useful short term fix, but there's nothing medical about it.

I expect IRX to follow IHL's business model, which is based upon medical science & intellectual property (IP) as the foundations.

This would mean 2 things could be in the works:

1. EC Pharma are developing a vaping medicine (potentially for an unmet medical condition), which they intend to patent.

2. IRX are working on acquiring or developing precise dosing technology, again which they intend to patent.

Once the IP is secured, then the trials are ready to begin & North American investors will enter the stock.

I note Philip Morris International invested $USD 20 million around 5 years ago in what looks to be a very average medical vape at best.

Nevertheless, that investment opened a lot of doors for Syqe, including Canada.

What is crystal clear is whichever vaping company nails the precise dosing technology first will be rained upon with money.

Another Vijay Sappani invested vaping company, Indose, is as close as I've seen.

Imo